Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Treatment Response and Long-Term Survival in Multiple Myeloma in the GMMG-HD4 Trial - Neither Profit All Molecular Entities Alike, Nor Are Remissions to Different Regimen Equal

Blood (2018) 132 (Supplement 1): 4485.

https://doi.org/10.1182/blood-2018-99-113284

Published: 2018

Journal Articles

Double Vs Single Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Long-Term Follow-up (10-Years) Analysis of Randomized Phase 3 Studies

Blood (2018) 132 (Supplement 1): 124.

https://doi.org/10.1182/blood-2018-99-112899

Published: 2018

Journal Articles

Phase 2 Study of Carfilzomib, Thalidomide, and Low-Dose Dexamethasone As Induction/Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma, the Carthadex Trial

Ruth Wester, Bronno van der Holt, PhD, Emelie Asselbergs, Mark van Duin, PhD, Sonja Zweegman, MD PhD, Marie Jose Kersten, MD PhD, Edo Vellenga, MDPhD, Marinus van Marwijk Kooy, MD, Okke de Weerdt, MD, Monique Minnema, Sarah Lonergan, MSc, Antonio Palumbo, MD, Henk M. Lokhorst, MD PhD, Annemiek Broijl, MD PhD, Pieter Sonneveld, MD PhD

Blood (2016) 128 (22): 1141.

https://doi.org/10.1182/blood.V128.22.1141.1141

Published: 2016

Journal Articles

Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)

Saad Z Usmani, MD FACP, Hareth Nahi, Maria-Victoria Mateos, MD PhD, Henk M. Lokhorst, MD PhD, Ajai Chari, MD, Jonathan L. Kaufman, MD, Philippe Moreau, Albert Oriol, MD, Torben Plesner, Professor, Lotfi Benboubker, MD PhD, Peter Hellemans, MD, Tara Masterson, Pamela L Clemens, PhD, Tahamtan Ahmadi, MD, Kevin Liu, Jesús San-Miguel, MD PhD

Blood (2016) 128 (22): 1149.

https://doi.org/10.1182/blood.V128.22.1149.1149

Published: 2016

Journal Articles

Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study

Shaji Kumar, MD, Meletios A Dimopoulos, Efstathios Kastritis, MD, Evangelos Terpos, Hareth Nahi, Hartmut Goldschmidt, MD, Jens Hillengass, MD, Xavier Leleu, Meral Beksac, MD, Melissa Alsina, MD, Albert Oriol, MD, Michele Cavo, MD, Enrique M. Ocio, MD PhD, Maria Victoria Mateos, Elizabeth K. O'Donnell, MD, Ravi Vij, MD MBA, Henk M. Lokhorst, MD PhD, Niels W.C.J. van de Donk, MD PhD, Chang-Ki Min, Tomer Mark, MD MSc, Ingemar Turesson, MD, PhD, Markus Hansson, MD, Heinz Ludwig, Sundar Jagannath, MD, Michel Delforge, MD PhD, Charalampia Kyriakou, MD PhD, Parameswaran Hari, MBBS, MD MRCP, Ulf-Henrik Mellqvist, MD PhD, Saad Z Usmani, MD FACP, Dominik Dytfeld, MD PhD, Ashraf Z Badros, MD, Philippe Moreau, Kihyun Kim, MD PhD, Paula Rodriguez Otero, MD, Jae Hoon Lee, MD, Chaim Shustik, MD, Daniel Waller, PhD, Wee Joo Chng, MD PhD, Shuji Ozaki, MD PhD, Je-Jung Lee, Javier de la Rubia, Hyeon Seok Eom, MD PhD, Laura Rosinol, MD PhD, Juan José Lahuerta, MD PhD, Anna Sureda, MD PhD, Jin Seok Kim, MD PhD, Brian G.M. Durie, MD

Blood (2016) 128 (22): 4414.

https://doi.org/10.1182/blood.V128.22.4414.4414

Published: 2016

Journal Articles

Reducing on-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors By Affinity Optimization

Esther Drent, MSc, Maria Themeli, MD PhD, Renée Poels, Niels W.C.J. van de Donk, MD PhD, Henk M. Lokhorst, MD PhD, Tuna Mutis, MD PhD

Blood (2016) 128 (22): 2170.

https://doi.org/10.1182/blood.V128.22.2170.2170

Published: 2016

Journal Articles

High-Parameter Mass Cytometry (CyTOF) Evaluation of Relapsed/Refractory Multiple Myeloma (MM) Pts (Pts) Treated with Daratumumab Supports Immune Modulation As a Novel Mechanism of Action

Homer Adams, III, PhD, Frederik Stevenaert, Jakub Krejcik, Koen Van der Borght, Tineke Casneuf, Tina Smets, Jaime Bald, Yann Abraham, Hugo Ceulemans, Greet Vanhoof, Tahamtan Ahmadi, MD, Saad Z Usmani, MD, Torben Plesner, Professor, Sagar Lonial, MD FACP, Berris van Kessel-Welmers, Henk M. Lokhorst, MD PhD, Tuna Mutis, MD PhD, Niels W.C.J. van de Donk, MD PhD, A. Kate Sasser

Blood (2016) 128 (22): 4521.

https://doi.org/10.1182/blood.V128.22.4521.4521

Published: 2016

Journal Articles

A High-Risk Survival Classifier for Multiple Myeloma

Rowan Kuiper, BSc, Annemiek Broyl, MD, Yvonne de Knegt, BSc, Martin H. van Vliet, PhD, Erik H. van Beers, PhD, Bronno van der Holt, PhD, Laila el Jarari, MSc, George Mulligan, PhD, Gareth Morgan, MD, Walter M Gregory, PhD, Hartmut Goldschmidt, MD, Henk M. Lokhorst, MD, Mark van Duin, PhD, Pieter Sonneveld, MD, PhD

Blood (2011) 118 (21): 1800.

https://doi.org/10.1182/blood.V118.21.1800.1800

Published: 2011

Journal Articles

Synergistic Action of the Human Inhibitory KIR Antibody IPH2102, and the Human CD38 Antibody Daratumumab to Enhance the Lysis of Primary Multiple Myeloma (MM) Cells in the Bone Marrow Mononuclear Cells (MNCs) From Myeloma Patients

Inger S. Nijhof, MD, Michel de Weers, PhD, Pascale Andre, PhD, Berris van Kessel, Henk M. Lokhorst, MD, Paul W.H.I. Parren, PhD, Yannis Morel, PhD, Tuna Mutis, MD PhD

Blood (2011) 118 (21): 1865.

https://doi.org/10.1182/blood.V118.21.1865.1865

Published: 2011

Journal Articles

Proteasome Inhibitors Sensitize Myeloma Cells to T Cell-Mediated Killing

Niels W.C.J. van de Donk, MD, PhD, Henk M. Lokhorst, MD, Maarten Emmelot, Tineke Aarts-Riemens, Douglas W. McMillin, PhD, Gullu Gorgun, PhD, Steffen Klippel, PhD, Eugen Dhimolea, PhD, Jana Jakubikova, PhD, Catriona A. Hayes, MD, Panisinee Lawasut, MD, Jake E Delmore, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD, Constantine S. Mitsiades, MD, PhD, Tuna Mutis, MD PhD

Blood (2011) 118 (21): 1838.

https://doi.org/10.1182/blood.V118.21.1838.1838

Published: 2011

Journal Articles

Carfilzomib Combined with Thalidomide and Dexamethasone (CARTHADEX) As Induction Treatment Prior to High-Dose Melphalan (HDM) in Newly Diagnosed Patients with Multiple Myeloma (MM). A Trial of the European Myeloma Network EMN

Pieter Sonneveld, MD, PhD, Emilie Hacker, Sonja Zweegman, MD PhD, Marie Jose Kersten, MD, PhD, Edo Vellenga, PhD, Marinus van Marwijk-Kooy, MD, Okke de Weerdt, MD, Sarah Lonergan, MSc, Antonio Palumbo, MD, Henk M. Lokhorst, MD

Blood (2011) 118 (21): 633.

https://doi.org/10.1182/blood.V118.21.633.633

Published: 2011

Journal Articles

The Human CD38 Monoclonal Antibody Daratumumab Improves the Anti-Myeloma Effect of Lenalidomide with Dexamethasone in Vitro

Michel de Weers, PhD, Michael van der Veer, Berris van Kessel, Joost M Bakker, PhD, Shulamiet Wittebol, MD, Paul WHI Parren, PhD, Henk M. Lokhorst, MD, Tuna Mutis, MD PhD

Blood (2011) 118 (21): 5106.

https://doi.org/10.1182/blood.V118.21.5106.5106

Published: 2011

Journal Articles

Identification of New Hematopoietic Minor Histocompatibility Antigen UTA2-1; Ready for Application in Antitumor Immunotherapy

Rimke Oostvogels, MD, Monique C. Minnema, MD PhD, Maureen van Elk, Robbert M Spaapen, PhD, Debbie van Baarle, PhD, Eric Spierings, PhD, Henk M. Lokhorst, MD, Tuna Mutis, MD PhD

Blood (2011) 118 (21): 2979.

https://doi.org/10.1182/blood.V118.21.2979.2979

Published: 2011

Journal Articles

Combining Information Regarding Chromosomal Aberrations t(4;14), Del(17p13) and the Copy Number of 1q21 with the International Staging System Classification Allows Stratification of Myeloma Patients Undergoing Autologous Stem Cell Transplantation: Results From the HOVON-65/GMMG HD4 Trial

Blood (2011) 118 (21): 332.

https://doi.org/10.1182/blood.V118.21.332.332

Published: 2011

Journal Articles

Reconstructing the Human Hematopoietic Niche: Opportunities for Studying Normal and Malignant Hematopoiesis,

Richard W Groen, PhD, Willy A Noort, PhD, Reinier Raymakers, MD, PhD, Henk-Jan Prins, Msc, Linda Aalders, Frans M Hofhuis, Berris van Kessel, Petra Moerer, Henk Rozemuller, PhD, Jan J. Schuringa, PhD, Joost de Bruijn, PhD, Michel de Weers, PhD, Paul W.H.I. Parren, PhD, Henk M. Lokhorst, MD, Tuna Mutis, MD PhD, Anton CM Martens, PhD

Blood (2011) 118 (21): 3412.

https://doi.org/10.1182/blood.V118.21.3412.3412

Published: 2011

Journal Articles

Microenvironment Shields Myeloma From Adoptive Immunotherapy by Cell Adhesion Mediated Immune Resistance (CAM-IR),

Sanne J de Haart, MD, Monique C. Minnema, MD PhD, Tineke Aarts-Riemens, Niels Bovenschen, PhD, Henk M. Lokhorst, MD, Tuna Mutis, MD PhD

Blood (2011) 118 (21): 4039.

https://doi.org/10.1182/blood.V118.21.4039.4039

Published: 2011

Journal Articles

Bone Marrow Neutralizes Human Regulatory T-Cells to Permit Graft-Versus-Tumor Immunity In Humanized Mice

Teun Guichelaar, PhD, Henk Rozemuller, PhD, Maarten Emmelot, Bianka Martini, Gert Storm, Henk M Lokhorst, MD, PhD, Anton Martens, PhD, Tuna Mutis, MD, PhD

Blood (2010) 116 (21): 1017.

https://doi.org/10.1182/blood.V116.21.1017.1017

Published: 2010

Journal Articles

In Vitro and In Vivo Efficacy of CD38 Directed Therapy with Daratumumab In the Treatment of Multiple Myeloma

Richard W Groen, Michael van der Veer, Frans M Hofhuis, Berris van Kessel, Michel de Weers, PhD, Paul W.H.I. Parren, PhD, Henk M Lokhorst, MD, PhD, Tuna Mutis, MD, PhD, Anton Martens, PhD

Blood (2010) 116 (21): 3058.

https://doi.org/10.1182/blood.V116.21.3058.3058

Published: 2010

Journal Articles

Induction of Potent Anti-Tumor Effects by Original and TCR-Redirected CD4 + Cytotoxic T Cells.

Robbert M Spaapen, Kelly van den Oudenalder, Maureen van Elk, Tineke Aarts, Teun Guichelaar, Richard WJ Groen, Andries C Bloem, Gert Storm, Anton C Martens, Henk M Lokhorst, MD, PhD, Tuna Mutis, MD, PhD

Blood (2009) 114 (22): 1333.

https://doi.org/10.1182/blood.V114.22.1333.1333

Published: 2009

Journal Articles

Host Dendritic Cell Vaccinations Combined with Donor Lymphocyte Infusions Induce Host and KLH Specific Immunity in Multiple Myeloma Patients.

Evelien Kneppers, Monique C. Minnema, MD, PhD, Tineke Aarts, Maarten E. Emmelot, Ineke Slaper-Cortenbach, PhD, Kasper Westinga, Tuna Mutis, MD, PhD, Henk M. Lokhorst, MD, PhD

Blood (2009) 114 (22): 2875.

https://doi.org/10.1182/blood.V114.22.2875.2875

Published: 2009

NARROW

Treatment Response and Long-Term Survival in Multiple Myeloma in the GMMG-HD4 Trial - Neither Profit All Molecular Entities Alike, Nor Are Remissions to Different Regimen Equal

Double Vs Single Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Long-Term Follow-up (10-Years) Analysis of Randomized Phase 3 Studies

Phase 2 Study of Carfilzomib, Thalidomide, and Low-Dose Dexamethasone As Induction/Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma, the Carthadex Trial

Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)

Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study

Reducing on-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors By Affinity Optimization

High-Parameter Mass Cytometry (CyTOF) Evaluation of Relapsed/Refractory Multiple Myeloma (MM) Pts (Pts) Treated with Daratumumab Supports Immune Modulation As a Novel Mechanism of Action

A High-Risk Survival Classifier for Multiple Myeloma

Synergistic Action of the Human Inhibitory KIR Antibody IPH2102, and the Human CD38 Antibody Daratumumab to Enhance the Lysis of Primary Multiple Myeloma (MM) Cells in the Bone Marrow Mononuclear Cells (MNCs) From Myeloma Patients

Proteasome Inhibitors Sensitize Myeloma Cells to T Cell-Mediated Killing

Carfilzomib Combined with Thalidomide and Dexamethasone (CARTHADEX) As Induction Treatment Prior to High-Dose Melphalan (HDM) in Newly Diagnosed Patients with Multiple Myeloma (MM). A Trial of the European Myeloma Network EMN

The Human CD38 Monoclonal Antibody Daratumumab Improves the Anti-Myeloma Effect of Lenalidomide with Dexamethasone in Vitro

Identification of New Hematopoietic Minor Histocompatibility Antigen UTA2-1; Ready for Application in Antitumor Immunotherapy

Combining Information Regarding Chromosomal Aberrations t(4;14), Del(17p13) and the Copy Number of 1q21 with the International Staging System Classification Allows Stratification of Myeloma Patients Undergoing Autologous Stem Cell Transplantation: Results From the HOVON-65/GMMG HD4 Trial

Reconstructing the Human Hematopoietic Niche: Opportunities for Studying Normal and Malignant Hematopoiesis,

Microenvironment Shields Myeloma From Adoptive Immunotherapy by Cell Adhesion Mediated Immune Resistance (CAM-IR),

Bone Marrow Neutralizes Human Regulatory T-Cells to Permit Graft-Versus-Tumor Immunity In Humanized Mice

In Vitro and In Vivo Efficacy of CD38 Directed Therapy with Daratumumab In the Treatment of Multiple Myeloma

Induction of Potent Anti-Tumor Effects by Original and TCR-Redirected CD4 + Cytotoxic T Cells.

Host Dendritic Cell Vaccinations Combined with Donor Lymphocyte Infusions Induce Host and KLH Specific Immunity in Multiple Myeloma Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only